Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tipranavir resistance associated mutations in protease inhibitor-naïve patients with HIV-1 subtype A/E infection.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 1 Nov 2008

Sungkanuparph Somnuek, Sukasem Chonlaphat, Manosuthi Weerawat, Wiboonchutikul Surasak, Piyavong Bucha, Chantratita Wasun

Abstract excerpt

BACKGROUND: Tipranavir-resistance associated mutations (TPV-RAMs) are often observed among patients with HIV-1 subtype A/E infection. Data regarding TPV resistance in subtype A/E is still limited. OBJECTIVES: To determine the prevalence of TPV-RAMs among protease inhibitor-naïve, HIV-1 subtype A/E infected patients. STUDY DESIGN: Genotypic resistance testing was conducted among HIV-1-infected patients who were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to CD4 Lymphocyte Count

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to HIV Protease

Share to Pyridines

Share to Pyrones

Share to Sulfonamides

Share to Viral Load

Source

Identifiers

PMID: 18701346
DOI: 10.1016/j.jcv.2008.07.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tipranavir resistance associated mutations in protease inhibitor-naïve patients with HIV-1 subtype A/E infection.PMID 18701346Read ↗

Comparison of protease inhibitor (PI) resistance-associated mutations between PI-naïve and PI-experienced HIV-1 infected patients in Thailand where subtype A/E is predominant.Semantic proximity Read ↗

Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes.Semantic proximity Read ↗

Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.Semantic proximity Read ↗

Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance MutationsSemantic proximity Read ↗

Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes.Semantic proximity Read ↗

Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.Semantic proximity Read ↗

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.Semantic proximity Read ↗

Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.Semantic proximity Read ↗

Prevalence of etravirine resistance associated mutations in HIV-1 strains isolated from infected individuals failing efavirenz: comparison between subtype B and non-B genetic variants.Semantic proximity Read ↗

Successful virological outcome in an HIV-infected individual with a three-class resistant variant and an insertion in the protease genome with a Tipranavir based regimen.Semantic proximity Read ↗

Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients.Semantic proximity Read ↗

Tipranavir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.